← Back to all trials
Active Not Recruiting
NCT02500849
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
Conditions: HIV
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 12
Sponsor: City of Hope Medical Center
Location: City of Hope Medical Center Duarte California
Summary
The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.
Eligibility Criteria
Inclusion Criteria:
* Maximum age 75 years for cohort 1 and 65 years for cohort 2.
* HIV-1 R5 seropositive with no evidence of CXCR4-tropic virus.
* On cART with undetectable HIV-1 (\
Source: ClinicalTrials.gov (NCT02500849). StuddyBuddy aggregates publicly available trial information.
